ALN-2232 Clinical Trials (2026): 1 Studies for Obesity

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

1 ALN-2232 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Obesity) and 156 total planned enrollment. 1 ALN-2232 clinical trial is actively recruiting. Most recent activity: NCT07463846 (Mar 2028).

ALN-2232 clinical trials at a glance: phase × recruitment status

PhaserecruitingTotal
P1/P211

Recruiting ALN-2232 clinical trials (1)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT07463846A Study to Evaluate ALN-2232 in Participants With ObesityP1/P2Obesity156Mar 2026

All ALN-2232 trials (1)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT07463846A Study to Evaluate ALN-2232 in Participants With ObesityP1/P2recruiting156Alnylam PharmaceuticalsMar 2026

ALN-2232 clinical trials: frequently asked questions

How many ALN-2232 clinical trials are there?
1 ALN-2232 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
Are ALN-2232 clinical trials recruiting in 2026?
Yes — 1 ALN-2232 trial is actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
What conditions is ALN-2232 being studied for?
ALN-2232 is being studied for Obesity. The trials are grouped by indication on this page.
Who sponsors ALN-2232 clinical trials?
The lead sponsor across the most ALN-2232 trials is Alnylam Pharmaceuticals. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming ALN-2232as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: